TickerWorth Open the interactive view →

Healthpeak Properties, Inc. (DOC) — Valuation Snapshot

Updated Nov 10, 2026 · REIT · FFO, book-value and yield view · descriptive, not a DCF, not advice

This is a REIT. A free-cash-flow DCF is structurally the wrong lens for property: heavy depreciation and continuous property capex swamp reported free cash flow, which is why REITs are valued on FFO/AFFO, net asset value and dividend yield. We show those lenses instead of a DCF number we would not stand behind.
Price
$20.62
Market cap
$14,970,507,264
52-week high
$22.95
52-week low
$15.70
Currency
USD
Exchange
NYSE

Healthpeak Properties, Inc. (DOC) is a real-estate investment trust, and a free-cash-flow discounted-cash-flow (DCF) model is structurally the wrong lens for one. A REIT's reported free cash flow is swamped by property depreciation and the continuous capital spending that maintaining a portfolio requires, which is why the industry is valued on funds from operations (FFO/AFFO), net asset value and dividend yield instead. We have the data to print a DCF number for DOC; we don't publish one because it would not mean what it appears to mean. What follows is how a REIT is actually read — descriptive, not a valuation, and not investment advice.

On the numbers we do have, DOC trades at a recent price of $20.62, a market capitalisation of about $14,970,507,264, sitting 68% of the way up its 52-week range ($15.70–$22.95), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing DOC's trading multiples against a sector benchmark. Here that gives P/E of 38.2× (richer than the peer median of 28.0×); Fwd P/E of 147.3× (richer than the peer median of 36.2×); P/B of 1.8× (cheaper than the peer median of 7.2×); P/S of 4.9× (cheaper than the peer median of 10.3×); EV/EBITDA of 16.5× (cheaper than the peer median of 19.9×); Dividend yield of 5.9% (cheaper than the peer median of 3.8%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. DOC shows a price-to-book (P/B) of 1.81 and book value of $11.41 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. DOC is in an up-trend (price above both its 50- and 200-day averages), trading -10.2% from its 52-week high. Over the past year the stock is +14.5%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

To be exact about what this page is not: we are not saying the numbers for DOC are unavailable. They are, and they are above. We are saying a discounted-cash-flow model is the wrong instrument for this kind of business, and publishing one anyway — because the inputs happen to exist — would be a precise answer to the wrong question. Refusing is the more useful answer, and it is the same rule we apply to every name in this category.

Relative valuation — DOC vs peers

MultipleDOCPeer median
P/E38.2×28.0×richer than
Fwd P/E147.3×36.2×richer than
P/B1.8×7.2×cheaper than
P/S4.9×10.3×cheaper than
EV/EBITDA16.5×19.9×cheaper than
Dividend yield5.9%3.8%cheaper than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

Price / book (P/B)
1.81
Book value / share
$11.41

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$19.75
200-day avg
$19.18
From 52-wk high
-10.2%
1-year momentum
+14.5%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive DOC view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.